Antibody Epitope Exposure and Neutralization of HIV-1
Keywords: CCR5; CD4-binding site; CD4bs; CXCR4; Cryo-electron tomography; EBV-transformed rhesus B cells; Enfuvirtide; Env-derived antigens; Golgi apparatus; HGN194; HIV envelope glycoprotein; HIV-1; MAb b13; Neutralization; SIV/HIV chimera; V3 Region; anti-viral antibody; antibody-dependent cellular cytotoxicity; complementarity determining; cytotoxic T cells; effector cells; epitope accessibility; gp120; monoclonal antibodies; neutralization; neutralizing antibodies; neutralizing antibody; non-neutralizing antibodies; oligomerization; vaccine
Document Type: Research Article
Publication date: November 1, 2010
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites